Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most prevalent neurodegenerative diseases today, with an estimated 55 million and 8.5 million people, respectively, afflicted by these diseases. As such, there is an urgent need to develop treatments that can prevent, delay the onset of, or mitigate symptoms. A key step in drug development is assessing the efficacy and toxicity of the novel therapy in in vivo models.
In this webinar, Inotiv scientists compare the various models available for AD and PD drug development and the behavioral, molecular, and histopathological endpoints that can be used to determine if treatments show enough therapeutic potential to progress through the pharmaceutical development pipeline.
This webinar:
- Reviews the symptoms and diagnostic biomarkers of AD and PD
- Discusses the most relevant preclinical AD and PD models
- Highlights our popular in vivo pharmacology models and the behavioral, molecular, and histopathological endpoints available for drug testing
Complete the form to access our on-demand webinar.
